REMARKS

A Restriction Requirement under 35 U.S.C. §121 has been entered in the present application. The Restriction Requirement identifies fourteen groups:

- Group I: Claims 1 and 3-4 (in part), drawn to a method of inhibiting TNF-alpha production;
- Group II: Claims 2 and 3-4 (in part), drawn to a method of inhibiting PDE4 activity;
- Group III: Claims 5, 7 (in part), 8 and 12-16 (in part), drawn to a method of treating or preventing a disease or a disorder ameliorated by reduction of TNF-alpha;
- Group IV: Claims 6, 7 (in part), 9-11 and 12-16 (in part), drawn to a method of treating or preventing cancer;
- Group V: Claims 17 and 24-32 (in part), drawn to a method of treating or preventing a disease ameliorated by PDE4;
- Group VI: Claims 18 and 27-32 (in part), drawn to a method of controlling cAMP levels in a cell;
- Group VII: Claims 19 and 27-32 (in part), drawn to a method of treating or preventing a list of diseases;
- Group VIII: Claims 20 and 27-32 (in part), drawn to a method of treating myelodysplastic syndrome;
- Group IX: Claims 21 and 27-32 (in part), drawn to a method of treating or preventing myeloproliferative disease;
- Group X: Claims 22 and 27-32 (in part), drawn to a method of treating or preventing pain;
- Group XI: Claims 23 and 27-32 (in part), drawn to a method of treating or preventing macular degeneration;

Group XII:

Claims 33-37, drawn to a pharmaceutical composition;

Group XIII:

Claims 38-42, drawn to a method of preparing a composition; and

Group XIV:

Claims 43-46, drawn to a enantiomerically pure salt.

In order to be fully responsive to the restriction requirement, Applicant provisionally elects, Group I (Claims 1, 3 and 4), drawn to a method of inhibiting TNF-alpha production, without prejudice to Applicant's right to prosecute any non-elected subject matter in one or more continuation, continuation-in-part or divisional applications.

Further, Applicant has been required to elect a single disease. Because Group I has been elected, it is not necessary to elect a single species election.

No fee is believed to be due in connection with this; however, should any fee be required, Applicant hereby authorizes that such fee be charged to Deposit Account No. 50-3013.

Respectfully submitted,

Date: June 27, 2007

By: Youn-Sil Moon

(Reg. No.) 52,042

For. Anthony M. Insogna

35,203

JONES DAY

222 East 41st Street

New York, New York 10017-6702

(212) 326-3939